Head-to-head evidence
HLX35 vs YH32364
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: EGFR x 4-1BB (CD137) · full Non-Small Cell Lung Cancer pipeline
HLX35
Developed by Shanghai Henlius Biotech
NCT05360381 · Phase 1 · status unknown
This is an open-label, non-randomized, single-arm dose-finding study with no control group, so it cannot demonstrate a treatment effect versus an alternative. No results have been posted yet.
YH32364
Developed by Yuhan Corporation
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: HLX35's landscape · YH32364's landscape